Layoffs at Carbon Robotics as firm “realigns costs due to broader economic conditions”
Seattle-based ag robotics firm Carbon Robotics has blamed “broader economic conditions” for an undisclosed number of lay…
Eastman launches biodegradable micropowder for skin care and SPF formulations
Eastman has launched Esmeri SK1N10, a biodegradable micropowder for skin care and SPF applications that aims to balance sustainability with consumer demand for sensorial performance. The release comes amid tightening synthetic ingredient regulations.
Staggered deadlines complicate EU citral compliance for natural beauty brands
The EU’s incoming citral restrictions contain staggered deadlines that could catch out some cosmetics companies. Personal care products containing the same molecule may have to exit shelves a month apart, creating compliance confusion.
Reservoir Farms expands to Pacific Northwest to accelerate physical AI
Ag robotics specialist Reservoir is opening a new site in Washington’s Yakima Valley as its on-farm community for …
Why Founders Are Returning to Agritech for a Second Shot
58 KEY POINTS A growing number of agritech founders are returning for a second attempt after their first venture failed.…
Muna’s oral Alzheimer’s candidate shifts age-associated markers in Phase 1
Why it matters: Alzheimer’s has no cure, and the EU-approved antibodies lecanemab and donanemab only slow decline in selected early-stage patients with confirmed amyloid and no more than one copy of the ApoE4 gene variant, while requiring infusions and monitoring for brain swelling and bleeding. Rather than targeting amyloid deposits, Muna’s pill aims to strengthen microglia, the brain’s immune cells, through TREM2, a receptor whose impaired function raises Alzheimer’s risk.
Arctic Therapeutics raises $21.5M to take autoimmune programs to clinic
Why it matters: With this round, Arctic is backing AT-002 and AT-003, treatments that could address gaps in the care of patients with autoimmune diseases such as uveitis, an eye inflammation that can threaten sight and whose steroid treatment increases the risk of glaucoma or cataracts. Meanwhile, its clinical-stage drugs target acne (AT-004) and dementia (AT-001), starting with HCCAA, a rare, fatal inherited disease that causes brain hemorrhages and dementia.
Luxury beauty in business: Puig, Dolce & Gabbana and Capsum push beyond core categories
Luxury giants are looking beyond their established strongholds for their next phase of growth, pushing into makeup and skin care with planned US and Asia expansions.
IMIO raises $12m to unlock nutrients trapped in crop residues with new generation of ‘dependable ag biologicals’
IMIO, a startup developing biologicals that break down crop residues to release nutrients that can boost crop yields and…
Evaxion reports durable responses; Novartis halts kidney trial; AstraZeneca signs AI deal
Evaxion reports sustained cancer vaccine responses at three years: Denmark’s Evaxion said all six patients in a Phase 2 extension maintained their responses without tumor progression after three years. The advanced melanoma patients received personalized peptide vaccine EVX-01 alone during the third year, following two years alongside Keytruda. The original 16-patient trial reported a 75% response rate with 25% of patients obtaining a complete response. The durability signal is encouraging, but the extension included only six of the 12 responders. Further findings will be presented at ESMO on October 24. Evaxion’s shares jumped 21.6% on Monday following the company’s announcement.